The Year in Biotech and What’s Ahead for 2026

Biotech stocks staged a dramatic turnaround in 2025, with the XBI well outpacing the S&P 500 despite concerns over leadership changes at the U.S. Food and Drug Administration, the Trump administration’s efforts to put constraints on drug pricing, and its broader cuts to health and science agencies. A pick-up in deal-making, along with falling interest rates, helped buoy the sector with growing anticipation for continued improvement in 2026. We sat down with Adam Feuerstein, senior biotech writer for STAT, for our annual review-preview edition, the noteworthy trends in the biotech sector 2025, and what’s in store at the upcoming JPMorgan Healthcare Conference and beyond in 2026.

You can listen to The Year in Biotech and What’s Ahead for 2026 online on Radio and Podcast. Open the player on this page to stream the available audio.

The Year in Biotech and What’s Ahead for 2026 is an episode from The Bio Report by Levine Media Group.

This episode is 38:15 long.

This episode was published on Dec 31, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.